Topical Antibiotic Bite Cream for Early Tick-Borne Infection Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Access to timely and effective antibiotic treatment for tick-borne infections, particularly Lyme disease, is challenging in remote settings due to the prescription-only nature of oral Tetracyclines and intravenous Cephalosporins, and these treatments pose risks such as allergic reactions and developmental issues in pregnant females and children.
Innovation Solution
A consumer package in the form of a topical composition containing Tetracycline or third-generation Cephalosporin, with optional anesthetic and anti-inflammatory agents, applied directly to the skin to enhance penetration and provide immediate treatment for tick bites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral Tetracyclines or intravenous Cephalosporins are used to treat tick-borne infections, then effective bactericidal action is achieved, but accessibility and ease of operation deteriorate due to prescription requirements and need for healthcare assessment
Solution Approach 1:
The patent changes the route of administration from oral or intravenous to topical application. This parameter change allows the antibiotic to be applied directly to the site of infection (tick bite location), eliminating the need for prescription and healthcare assessment while maintaining effective local concentrations of the antibiotic at the infection site.
Solution Approach 2:
The patent introduces a topical cream or ointment formulation as an intermediary vehicle to deliver the antibiotic directly to the infection site. This intermediary enables the antibiotic to bypass the prescription requirement and complex administration routes, providing direct local treatment while the carrier formulation ensures proper delivery and penetration.
2Reliability
If oral Tetracyclines are used to treat tick-borne infections, then effective bactericidal action is achieved, but harmful side effects increase including allergic reactions, GI flora disruption, and developmental issues in pregnant females and children
Solution Approach 1:
The patent applies the antibiotic locally at the site of infection rather than systemically throughout the body. By formulating a topical preparation that delivers the antibiotic directly to the tick bite location, the treatment achieves effective local concentrations while minimizing systemic absorption and associated side effects such as allergic reactions, GI flora disruption, and developmental issues.
Solution Approach 2:
The patent extracts the harmful systemic effects by removing the antibiotic from systemic circulation and confining its action to the local infection site. The topical formulation ensures the antibiotic remains localized at the application site, extracting the problematic systemic exposure while preserving the therapeutic bactericidal action against Borrelia burgdorferi.
3Reliability
If timely antibiotic treatment is administered to prevent Lyme Disease, then protection against infection manifestations is achieved, but time loss increases due to difficulty in obtaining prompt healthcare assessment and prescription in remote settings
Solution Approach 1:
The patent enables preliminary action by allowing individuals to immediately apply the antibiotic topical preparation at the site of a tick bite without waiting for healthcare assessment or prescription. This preliminary local treatment can be administered right away, preventing the infection from establishing before professional medical care is sought, thereby eliminating the time delay associated with obtaining prescriptions in remote settings.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The topical composition effectively delivers antibiotics to the site of infection, reducing the risk of systemic side effects and providing rapid bactericidal action against Borrelia burgdorferi, thereby preventing Lyme disease.
Implementation Method 1
a carrier that has skin penetration enhancement properties
Data Source
AI summary
The topical composition includes an amount of an antibiotic and a carrier that has skin penetration enhancement properties. The composition can include about 5 wt % Lidocaine, about 5 wt % Ketoprofen and about 5 wt % Doxycycline. The composition is readily formed as a consumer package. The composition has efficacy as a bite treatment and in particular bacteria conveyed via a tick bite.